Breaking News Instant updates and real-time market news.

TEVA

Teva

$14.37

-0.1 (-0.69%)

, MYL

Mylan

$22.18

-0.57 (-2.51%)

09:17
05/13/19
05/13
09:17
05/13/19
09:17

Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo

Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."

TEVA

Teva

$14.37

-0.1 (-0.69%)

MYL

Mylan

$22.18

-0.57 (-2.51%)

AMRX

Amneal Pharmaceuticals

$10.42

-0.65 (-5.87%)

NVS

Novartis

$81.86

0.82 (1.01%)

LCI

Lannett

$6.85

0.12 (1.78%)

PFE

Pfizer

$40.72

0.08 (0.20%)

RDY

Dr. Reddy's

$41.34

-0.52 (-1.24%)

  • 13

    May

  • 14

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 23

    May

  • 31

    May

  • 05

    Aug

TEVA Teva
$14.37

-0.1 (-0.69%)

04/22/19
CANT
04/22/19
NO CHANGE
Target $75
CANT
Overweight
Emergent shares largely pricing in Teva approval, says Cantor Fitzgerald
The FDA on Friday granted Teva Pharmaceutical (TEVA) final approval for its generic version of Narcan, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as largely anticipated following the expiration of Teva's 30- month stay last month. Shares of Emergent BioSolutions (EBS) are down 18.7% since reporting Q4 earnings, largely driven by the anticipation of a final approval of Teva's generic naloxone, says Folkes. While Friday's approval is a negative and will continue to create an overhang on Emergent shares, the recent weakness has "adequately accounted for this overhang," he contends. As such, Folkes keeps an Overweight rating on Emergent BioSolutions with a $75 price target.
05/01/19
WELS
05/01/19
NO CHANGE
Target $18
WELS
Market Perform
Teva shares reflect much of bad news, says Wells Fargo
Wells Fargo analyst David Morris kept his Market Perform rating and $18 price target on Teva (TEVA) ahead of its Q1 earnings tomorrow, saying investors have "low expectations" for the quarter after "weak-ish" Sandoz results from Novartis (NVS). The analyst also points to IQVIA (IQV) sales and prescriptions data indicating that Teva generic sales were down 12% in March, 10% in February, and 13% in January, though the decline are "much smaller" than seen in U.S. generics during 2018. Morris further expects Teva to address the risk of opioid litigation that became a concern during the quarter in its earnings call.
05/03/19
CANT
05/03/19
NO CHANGE
Target $16
CANT
Neutral
Teva price target lowered to $16 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Teva Pharmaceutical to $16 from $25 and keeps a Neutral rating on the shares following the company's Q1 results. The analyst would like to see increased sales and earnings visibility before getting more positive on the stock.
04/24/19
WELS
04/24/19
NO CHANGE
WELS
Sandoz results should not be seen as positive for generics, says Wells Fargo
Wells Fargo analyst David Maris sees nothing in the Q1 results from Novartis (NVS) unit Sandoz that points to a dramatically improving U.S. generic pricing environment. We would tot read the Sandoz results as a positive for generic companies such as Teva (TEVA) and Mylan (MYL), and commentary about generic Copxone pricing trends is a negative, Maris tells investors in a research note. He believes Sandoz trends are important to watch as a potential read-through for other generic drug company results. Novartis continues to see higher generic headwinds in the remainder of 2019, Maris points out, citing comments from the earnings call.
MYL Mylan
$22.18

-0.57 (-2.51%)

05/08/19
05/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Market Perform from Outperform at Wells Fargo with analyst David Maris saying Mylan reported "disappointing" results which missed consensus on several key metrics including revenue and revenue by segment. 2. Inogen (INGN) downgraded to Neutral from Overweight at JPMorgan with analyst Robert Marcus saying the company's in-line Q1 results were overshadowed by a $25M reduction to guidance. 3. Fortive (FTV) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Joshua Pokrzywinski citing the stock's valuation after a 29% year-to-date advance as well as the sector valuation of "high quality industrials". 4. Farmer Bros. (FARM) downgraded to Neutral from Buy at Roth Capital with analyst Gerry Sweeney saying the company's results were hurt by significant operating issues and Mike Keown stepped down as CEO. 5. 2U (TWOU) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick noting the company reported Q1 and lowered its fiscal year revenue guidance, primarily accounting for schools tightening their admissions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/19
RBCM
05/08/19
NO CHANGE
Target $26
RBCM
Outperform
Mylan price target lowered to $26 from $45 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Mylan to $26, saying yesterday's 24% stock price plunge and investor frustration are "justified", even though the magnitude of the sell-off may be "overly punitive." The analyst cites the management's forecasting challenges, "delays in responding to industry change", and governance issues as factors in the stock price decline. Stanicky also keeps his Outperform rating and expects the pressure on the company's board to facilitate change to increase.
05/08/19
WELS
05/08/19
DOWNGRADE
Target $22
WELS
Market Perform
Wells Fargo downgrades Mylan to Market Perform after 'disappointing' quarter
Wells Fargo analyst David Maris downgraded Mylan to Market Perform from Outperform and lowered his price target for the shares to $22 from $33. The stock closed yesterday down 24%, or $6.73, to $21.53. Mylan reported "disappointing" results which missed consensus on several key metrics including revenue and revenue by segment, Maris tells investors in a research note. The analyst says he's downgrading the shares as Mylan continues to perform below his expectations. Even after yesterday's selloff, Maris believes the risks outweigh the valuation given the earnings uncertainty. Further, the lack of any outcome or major announcement about the strategic review suggests the review is not going to result in any material changes, according to Maris.
05/07/19
WELS
05/07/19
DOWNGRADE
Target $22
WELS
Market Perform
Mylan downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst David Maris downgraded Mylan to Market Perform from Outperform and lowered his price target for the shares to $22 from $33.
AMRX Amneal Pharmaceuticals
$10.42

-0.65 (-5.87%)

03/08/19
LEER
03/08/19
DOWNGRADE
LEER
Market Perform
Amneal Pharmaceuticals downgraded to Market Perform at SVB Leerink
03/08/19
LEER
03/08/19
DOWNGRADE
Target $12
LEER
Market Perform
SVB Leerink downgrades Amneal to Market Perform on lower 2019 sales outlook
SVB Leerink analyst Ami Fadia downgraded Amneal Pharmaceuticals to Market Perform from Outperform and lowered her price target for the shares to $12 from $16. Given the slower than anticipated pace of new product approvals as well as recent management comments on new product contribution, the analyst now forecasts a lower sales growth in 2019 of 2.2% versus her previous high-single-digit growth rate. Fadia now believes it will take longer for Amneal to realize the potential value of its complex generics portfolio.
03/19/19
RHCO
03/19/19
INITIATION
Target $16
RHCO
Buy
Amneal Pharmaceuticals initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert started Amneal Pharmaceuticals with a Buy rating and $16 price target. The analyst likes the prospects for Amneal's "broad and diverse" portfolio of on-market products and "large" pipeline of generics that he believes could drive above-average revenue and EBITDA growth over the next few years.
01/03/19
LEER
01/03/19
NO CHANGE
Target $19
LEER
Outperform
Amneal Pharmaceuticals price target lowered to $19 from $25 at Leerink
Leerink analyst Ami Fadia lowered her price target for Amneal Pharmaceuticals to $19 from $25 to reflect a more conservative erosion of base business products like Gx Aggrenox, Vagifem, and Voltaren Gel into 2019, and a more conservative view on new product launches given continued lack of visibility into the timing and magnitude of such opportunities. The analyst reiterates an Outperform rating on the shares.
NVS Novartis
$81.86

0.82 (1.01%)

05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
05/13/19
CANT
05/13/19
NO CHANGE
Target $405
CANT
Neutral
Regeneron price target lowered to $405 from $441 at Cantor Fitzgerald
Cantor Fitzgerald analyst Regeneron Pharmaceuticals (REGN) to $405 from $441 saying the company's expenses are tracking higher than his projections. Further, he thinks investor concerns about Novartis' (NVS) brolucizumab approval in eye and increased atopic dermatitis competition remain headwinds for share upside. The analyst reiterates a Neutral rating on Regeneron following its Q1 results.
LCI Lannett
$6.85

0.12 (1.78%)

03/19/19
RHCO
03/19/19
INITIATION
Target $9
RHCO
Hold
Lannett initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Lannett with a Hold rating and $9 price target. The analyst says that while the stock's most important overhang has been removed with the loss of levothyroxine, he sees the risk/reward as relatively balanced at current share levels.
08/20/18
BMOC
08/20/18
NO CHANGE
BMOC
Market Perform
Lannett price target lowered to $8 from $19 at BMO Capital
BMO Capital analyst Gary Nachman said JSP's decision to not renew its agreement with Lannett (LCI) and go with Amneal Pharmaceuticals (AMRX) is an "unfortunate development" that impacts three products, including Levothyroxine, which accounts for about 35-40% of Lannett revenue and is "very profitable." He lowered his estimates "significantly" due to this "major setback" and cut his price target on Lannett shares to $8 from $19 while maintaining a Market Perform rating on the shares.
08/20/18
08/20/18
DOWNGRADE

Market Perform
Lannett downgraded to Market Perform as JSP walks away from renewal at Raymond James
As previously reported, Raymond James analyst Elliot Wilbur downgraded Lannett to Market Perform from Outperform after Jerome Stevens terminated its strategic distribution agreement with the company, a deal that provided Lannett with several key products but mainly levothyroxine, which is expected to account for 35% of FY18 sales and 44% of gross profit. From a monetary perspective, the analyst believes it makes "zero sense" why JSP would walk away from the deal, inflicting significant damage on its own holdings of Lannett shares. This suggests either JSP has no confidence in the recovery value of its holdings from current levels or has sold down or hedged a substantial portion of its holdings despite prior representations from Lannett management to the contrary, Wilbur contends.
08/20/18
RAJA
08/20/18
DOWNGRADE
RAJA
Market Perform
Lannett downgraded to Market Perform from Outperform at Raymond James
PFE Pfizer
$40.72

0.08 (0.20%)

02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/19
ROTH
05/07/19
NO CHANGE
Target $51
ROTH
Buy
Eidos Therapeutics raised to $51 from $28 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer's (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.
05/09/19
BARD
05/09/19
NO CHANGE
BARD
Outperform
Baird names Sarepta a 'Fresh Pick' ahead of Pfizer data
Baird analyst Brian Skorney named Sarepta as a "Fresh Pick" ahead of the report of competitive data due in late June from Pfizer's (PFE) Duchenne muscular dystrophy program that he predicts will "fall flat." If that turns out to be the case, it should remove the most significant overhang on Sarepta shares, contends Skorney, who keeps an Outperform rating on Sarepta.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.
RDY Dr. Reddy's
$41.34

-0.52 (-1.24%)

02/11/19
LSCM
02/11/19
NO CHANGE
Target $14
LSCM
Buy
Aquestive downside from generic Suboxone already priced in, says Lake Street
Based on the February 5 denial by the Court of Appeals for the Federal Circuit of Indivior's appeals regarding the preliminary injunction against Dr. Reddy's Laboratories (RDY), the court should be issuing its mandate today, allowing Dr. Reddy's and Alvogen to come to market with their Suboxone generics, Lake Street analyst Thomas Flaten tells investors in a research note. The analyst values the Suboxone revenue stream at $2-$4 per Aquestive Therapeutics (AQST) share and believes any related downside is more than priced into the stock. As such, he reiterates a Buy rating on Aquestive with a $14 price target.
02/20/19
LSCM
02/20/19
NO CHANGE
Target $17
LSCM
Buy
Aquestive Therapeutics price target raised to $17 from $14 at Lake Street
Lake Street analyst Thomas Flaten lowered his 2019 revenue estimate for Aquestive Therapeutics (AQST) to $43.5M from $67M after the Court of Appeals for the Federal Circuit issued its mandate yesterday, vacating the preliminary injunction that had barred Dr. Reddy's Laboratories (RDY) from entering the market. The analyst, however, believes any related downside has been more than priced into shares of Aquestive Therapeutics. He reiterates a Buy rating on the name and raised his price target for the stock to $17 from $14.
02/19/19
LYON
02/19/19
UPGRADE
LYON
Buy
Dr. Reddy's upgraded yesterday to Buy from Outperform at CLSA
02/11/19
GUGG
02/11/19
NO CHANGE
GUGG
Neutral
Patent ruling positive for Celgene and Bristol-Myers, says Guggenheim
Guggenheim analyst Seamus Fernandez said the Patent Trial and Appeal Board's decision denying Dr. Reddy's (RDY) inter partes review petition seeking to invalidate 3 Revlimid myelodysplastic syndrome patents expiring April 2023 is a positive for Celgene's (CELG) shareholders as well as for the combination with Bristol-Myers (BMY). Consistent with his below-consensus estimates for Revlimid, he continues to view a broad settlement, beginning with Dr. Reddy's, as the most likely outcome, Fernandez tells investors. He keeps a Neutral rating on Bristol-Myers shares.

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$43.17

0.82 (1.94%)

, AEO

American Eagle

$15.40

0.63 (4.27%)

19:34
08/18/19
08/18
19:34
08/18/19
19:34
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

CMCSA

Comcast

$43.17

0.82 (1.94%)

AEO

American Eagle

$15.40

0.63 (4.27%)

MO

Altria Group

$46.48

1 (2.20%)

CMCSK

Comcast

$0.00

(0.00%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 04

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

19:27
08/18/19
08/18
19:27
08/18/19
19:27
Periodicals
Trump does not want to do business with Huawei, Reuters reports »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$2.61

0.04 (1.56%)

19:25
08/18/19
08/18
19:25
08/18/19
19:25
Earnings
X Financial reports Q2 EPS 31c, consensus 22c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

VJET

Voxeljet

$1.64

-0.05 (-2.96%)

18:44
08/18/19
08/18
18:44
08/18/19
18:44
Recommendations
Voxeljet analyst commentary at Piper Jaffray »

Voxeljet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$206.44

4.71 (2.33%)

18:40
08/18/19
08/18
18:40
08/18/19
18:40
Periodicals
Apple CEO warns Trump about China tariffs, Reuters reports »

President Donald Trump…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$206.44

4.71 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$34.98

0.64 (1.86%)

, CMCSA

Comcast

$43.17

0.82 (1.94%)

18:05
08/18/19
08/18
18:05
08/18/19
18:05
On The Fly
Box Office Battle: 'Good Boys' wins weekend with $21M debut »

"Box Office Battle" is…

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.72

0.64 (1.16%)

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

DIS

Disney

$135.19

1.79 (1.34%)

VIAB

Viacom

$26.02

0.09 (0.35%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Oct

  • 27

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.